Subsequently, in November 2017, the FCA further considered
the obviousness test in Ciba Speciality Chemicals Water Treatment v SNF Inc, 2017 FCA 225.
The FCA clarified that step 3 of the 4 - step
obviousness test that was provided in Plavix 1 requires a comparison between the inventive concept (or the claim as construed) and the prior art, not the common general knowledge, to identify the differences, if any, between the inventive concept and the prior art.
As the Federal Court continues to interpret and apply the 2008 Sanofi SCC
obviousness test (Apotex Inc. v. Sanofi - Synthelabo Canada Inc., 2008 SCC 61 («Sanofi»)-RRB-, one important step — defining the «inventive concept» — has not always been defined consistently.
A number of Supreme Court justices had harsh words for the Federal Circuit, terming
its obviousness test «gobbledygook» (Scalia) and «meaningless» (Roberts).
Not exact matches
Another big case examines the patentability of diagnostic
testing, and a third case in the pipeline could rethink the standard the Court set in 1983 to
test the
obviousness of what is patentable — a case that could call into question the validity of hundreds of thousands of existing patents.
Despite a few catastrophes, only one happens to be shown on - screen, and the
obviousness of the dummies used in place of humans doesn't allow this would - be disaster to pass the snicker
test.
«The law was straightforward for a long time in Canada,» says Van Barr, «but it changed... with [the Supreme Court case Apotex Inc. v Sanofi - Synthelabo Canada Inc], which introduced a new
test for
obviousness, and «since that time the courts have been interpreting and reinterpreting what that
test means.»
Motorcycle racing on - road / off - road Motorcycle riding on - road / off - road Motorcycle safety on - road / off - road Motorcycle riding with passenger Motorcycle accident reconstruction Motorcycle design Motorcycle
testing on - road / off - road Motorcycle mechanics and repair Motorcycle valuation Motorcycle training (instruction) Motorcycle failure analysis ATV training (instruction) ATV repair ATV failure analysis ATV transmission design ATV design ATV accident reconstruction ATV racing ATV riding ATV
testing OEM vs. after - market parts, systems OEM vs. counterfeit auto parts Motocross racing, riding, teaching,
testing Racetrack design, construction, safety Off highway vehicle park design and construction Warning signs and placement of same Automobile accident reconstruction Automobile restraint systems Automobile failure analysis Automobile racing on - road / off - road Safety engineering Bicycle accidents Mechanism of injuries reconstruction Recreation vehicle accident Scooters — electric, engine, self - powered Heavy truck accident reconstruction Automobile clutches and transmissions Tire
testing Tire research & development Tire skid analysis Tire failure analysis Mechanical Engineer Engineering management Materials handling science Brain injury mechanism, thresholds in impacts Brain injury — inertial Trailer accident reconstruction Trailer
testing & design Machinist Fires cause & origin Motorcycle & ATV fire investigation A.S.E. Master Technician Safety helmets Marine accident reconstruction Photography Photographic forensic analysis Videographic forensic analysis Electrical systems troubleshooting Heavy equipment Construction tools Hand tools — use & safety Bus accident reconstruction Product warnings Equipment guards Barriers and catch fences Patent cases, infringement,
obviousness, technical comparison
In introducing this four part analysis, the Supreme Court was critical of the application of previous «
test» for
obviousness from Beloit (Beloit Canada Ltd. v. Valmet OY (1986), 8 C.P.R. (3d) 289), saying, «the courts have often tended to treat the word formulation of Beloit as if it were a statutory prescription that limits the
obviousness inquiry.»
This Article
tests this argument's plausibility and determines the characteristics of patents without innovation by analyzing 980 litigated patents subject to anticipation or
obviousness decisions between 2000 and 2010.
CIPO announced a new Practice Direction on the
test that the Patent Office will apply in assessing
obviousness in light of Rothstein J.'s judgment for the Court in Apotex Inc. v. Sanofi - Synthelabo Canada, Inc. [2008 SCC 61]
In April 2017, in Bristol - Myers Squibb Canada Co v Teva Canada Limited (2017 FCA 76), the Federal Court of Appeal (FCA) clarified the
test for assessing
obviousness subsequent to the Supreme Court of Canada's (SCC) 2008 seminal decision on this
test in Apotex c v Sanofi - Synthelabo Canada Inc, 2008 SCC 61 (Plavix 1).